WOBURN, Mass., Nov. 26 /PRNewswire/ -- Covaris Incorporated today announced that during the summer of 2008, the company celebrated the shipment of its 500th instrument unit and continued another successful year throughout 2008. To accommodate this rapid business growth, Covaris is both strengthening its sales and marketing organization as well as implementing a 50% expansion of its main facility.
The Covaris business was built upon the proprietary and patented AFA(TM) (Adaptive Focused Acoustics) technology. The AFA technology has the ability of impart both thermal and non-contact control of application processes, which, in many cases, could not be obtained prior to the development of AFA technology. This unique and sustainable competitive advantage enables Covaris to develop a broad range of applications in Genomics, Proteomics and Drug Discovery research.
"There has been an increased systematic acceptance of our technology over the past few years. We are pleased to see our sample preparation tools gaining market acceptance and incorporated into daily research investigations throughout research institutions and pharmaceutical companies, such as the Broad Institute, GlaxoSmithKline and Merck," said Jim Laugharn, President and CEO of Covaris, "with the help of our customers, we have developed and optimized solutions for various key applications, such as DNA shearing for next-gen sequencing, RNA extraction for gene expression profiling, analyte and small molecule extraction from difficult tissue samples, compound formulation, and ADME/Tox."
"I'm truly impressed with the solid technology and product platform
Covaris has developed and its experienced team of people with well-balanced
knowledge ranging from acoustic physics, mechanical engineering to biophysics
and molecular biology," commented Jennifer Wu, the newly hired Director of
Marketing, "I'm honored and excited to join Covaris to further ex
|SOURCE Covaris Incorporated|
Copyright©2008 PR Newswire.
All rights reserved